Literature DB >> 9205065

A high ratio of insulin-like growth factor II/insulin-like growth factor binding protein 2 messenger RNA as a marker for anaplasia in meningiomas.

A C Nordqvist1, M Peyrard, H Pettersson, T Mathiesen, V P Collins, J P Dumanski, M Schalling.   

Abstract

Insulin-like growth factors (IGFs) I and II have been implicated as autocrine or paracrine growth promoters. These growth factors bind to specific receptors, and the response is modulated by interaction with IGF-binding proteins (IGFBPs). We observed a strong correlation between anaplastic/atypical histopathology and a high IGF-II/IGFBP-2 mRNA ratio in a set of 68 sporadic meningiomas. A strong correlation was also found between clinical outcome and IGF-II/IGFBP-2 ratio, whereas previously used histochemical markers were less correlated to outcome. We suggest that a high IGF-II/IGFBP-2 mRNA ratio may be a sign of biologically aggressive behavior in meningiomas that can influence treatment strategies. We propose that low IGFBP-2 levels in combination with increased levels of IGF-II would result in more free IGF-II and consequently greater stimulation of proliferation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205065

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

Review 2.  The IGF/IGFBP system in CNS malignancy.

Authors:  W Zumkeller; M Westphal
Journal:  Mol Pathol       Date:  2001-08

3.  Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

Authors:  F Frasca; G Pandini; P Scalia; L Sciacca; R Mineo; A Costantino; I D Goldfine; A Belfiore; R Vigneri
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

Review 4.  IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth?

Authors:  W Zumkeller
Journal:  Mol Pathol       Date:  2001-10

Review 5.  Molecular pathogenesis of meningiomas.

Authors:  Arie Perry; David H Gutmann; Guido Reifenberger
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

Review 6.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

7.  Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.

Authors:  Mark A Watson; David H Gutmann; Kelly Peterson; Michael R Chicoine; Bette K Kleinschmidt-DeMasters; Henry G Brown; Arie Perry
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness.

Authors:  Ann-Christin Sandberg Nordqvist; Tiit Mathiesen
Journal:  J Neurooncol       Date:  2002-03       Impact factor: 4.130

Review 9.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03

10.  Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas.

Authors:  Mahlon D Johnson; Mary O'Connell; Fran Vito; Robert S Bakos
Journal:  J Neurooncol       Date:  2008-11-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.